Copper Peptide

Copper peptide refers to a class of compounds, most commonly GHK-Cu, in which a small peptide is bound to a copper ion. GHK is a naturally occurring tripeptide found in human plasma that appears to decline with age, and its copper-bound form has been studied extensively for roles in tissue repair, collagen synthesis, and antioxidant activity. While copper peptides are widely known in topical skincare, this profile addresses use in reconstituted, injectable protocols as researched for skin and connective tissue support. Research spans several decades and includes both in vitro and animal studies, alongside more limited human data. As with other copper-containing compounds, dosing and long-term safety in injectable form require caution. Reported benefits include studied for supporting collagen and elastin synthesis in skin and connective tissue, investigated for antioxidant and anti-inflammatory signaling properties, explored in wound healing research contexts.

Reported ranges run 1-3 mg. A low protocol is 1 mg once daily or every other day, and a high protocol is 3 mg once daily, at the higher end of ranges discussed in research and community protocols. This is reference information, not a dosing recommendation.

Short, generally cited in the range of minutes to a few hours for the peptide-copper complex, though tissue effects may persist beyond plasma clearance.. That is what sets the dosing frequency, and it is why the timing guidance is evening.

Subcutaneous: into fat, under the skin. This profile covers copper peptide as used in reconstituted, injectable/subcutaneous protocols rather than topical cosmetic formulations.

Multi-week cycles of daily or near-daily dosing are commonly described on, followed by Periodic breaks are often suggested to avoid cumulative copper exposure off. Monitoring of copper levels may be advisable with extended or repeated cycles given copper's potential for tissue accumulation.

Reported side effects include injection site irritation or redness, potential for copper accumulation with excessive or prolonged use, limited long-term human safety data for injectable administration, possible allergic or sensitivity reactions in susceptible individuals. Evidence level for this compound is moderate evidence.